IBA Molecular is a global leader in the manufacturing and distribution of radiopharmaceutical products that are used in Positron Emission Tomography (“PET”) and Single-Photon Emission Computed Tomography (“SPECT”) diagnostic and therapeutic molecular imaging procedures. The Company’s radiopharmaceutical products help to enhance patient outcomes and lower costs by facilitating personalized medical treatment and providing precise and rapid diagnosis. IBA Molecular has over 50 locations in the U.S., Europe and Asia and employs over 1,000 people.
SK Capital Partners acquired a majority interest in IBA Molecular from Ion Beam Applications S.A. in April 2012.
In 2015, SK Capital divested IBA Molecular’s US operations to a strategic acquirer with the remaining business sold to CapVest Partners in 2016.